MA52216A - Méthodes de traitement de la colite ulcéreuse - Google Patents
Méthodes de traitement de la colite ulcéreuseInfo
- Publication number
- MA52216A MA52216A MA052216A MA52216A MA52216A MA 52216 A MA52216 A MA 52216A MA 052216 A MA052216 A MA 052216A MA 52216 A MA52216 A MA 52216A MA 52216 A MA52216 A MA 52216A
- Authority
- MA
- Morocco
- Prior art keywords
- ulcerative colitis
- treatment methods
- treatment
- methods
- ulcerative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650314P | 2018-03-30 | 2018-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52216A true MA52216A (fr) | 2021-02-17 |
Family
ID=66429483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052216A MA52216A (fr) | 2018-03-30 | 2019-03-28 | Méthodes de traitement de la colite ulcéreuse |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210032325A1 (fr) |
| EP (2) | EP4327866A3 (fr) |
| JP (3) | JP7119114B2 (fr) |
| KR (1) | KR102552693B1 (fr) |
| CN (1) | CN111936165A (fr) |
| AU (2) | AU2019243283C1 (fr) |
| BR (1) | BR112020018099A2 (fr) |
| CA (1) | CA3095297A1 (fr) |
| DK (1) | DK3773715T3 (fr) |
| EA (1) | EA202091989A1 (fr) |
| FI (1) | FI3773715T3 (fr) |
| IL (1) | IL277514A (fr) |
| MA (1) | MA52216A (fr) |
| MX (1) | MX2020010269A (fr) |
| SG (1) | SG11202009526RA (fr) |
| TW (1) | TWI744617B (fr) |
| WO (1) | WO2019191464A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
| CA3170677A1 (fr) * | 2020-02-14 | 2021-08-19 | Janssen Biotech, Inc. | Methode sure et efficace de traitement de la rectocolite hemorragique avec un anticorps anti-il-12/il23 |
| JP7423815B2 (ja) | 2020-10-20 | 2024-01-29 | セトラスホールディングス株式会社 | 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム |
| MX2023007933A (es) * | 2021-01-06 | 2023-09-15 | Abbvie Inc | Métodos para tratar la enfermedad de crohn y la colitis ulcerosa. |
| AU2022276189A1 (en) * | 2021-05-20 | 2024-01-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| EP4347018A1 (fr) * | 2021-05-28 | 2024-04-10 | Eli Lilly and Company | Régulation d'anticorps anti-il-23p19 de gènes impliqués dans la rectocolite hémorragique |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1896073B1 (fr) * | 2005-06-30 | 2013-03-06 | Janssen Biotech, Inc. | Anticorps anti-il-23, compositions, méthodes et utilisations |
| ES2517420T3 (es) | 2005-12-29 | 2014-11-03 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| CA2741566A1 (fr) * | 2008-11-03 | 2010-06-03 | Schering Corporation | Biomarqueurs de maladie inflammatoire de l'intestin et procedes apparentes du traitement |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CN103282382B (zh) * | 2010-11-04 | 2017-11-03 | 勃林格殷格翰国际有限公司 | 抗il‑23抗体 |
| TWI636063B (zh) | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合ｉｌ－２３之抗體 |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| JP2021515770A (ja) * | 2018-03-05 | 2021-06-24 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ−２３特異的抗体を用いたクローン病の治療方法 |
-
2019
- 2019-03-27 TW TW108110767A patent/TWI744617B/zh active
- 2019-03-28 MA MA052216A patent/MA52216A/fr unknown
- 2019-03-28 FI FIEP19722256.5T patent/FI3773715T3/fi active
- 2019-03-28 BR BR112020018099-8A patent/BR112020018099A2/pt unknown
- 2019-03-28 US US16/981,915 patent/US20210032325A1/en active Pending
- 2019-03-28 EP EP23215626.5A patent/EP4327866A3/fr active Pending
- 2019-03-28 JP JP2020552872A patent/JP7119114B2/ja active Active
- 2019-03-28 KR KR1020207027982A patent/KR102552693B1/ko active IP Right Grant
- 2019-03-28 SG SG11202009526RA patent/SG11202009526RA/en unknown
- 2019-03-28 CA CA3095297A patent/CA3095297A1/fr active Pending
- 2019-03-28 CN CN201980023563.3A patent/CN111936165A/zh active Pending
- 2019-03-28 EP EP19722256.5A patent/EP3773715B1/fr active Active
- 2019-03-28 DK DK19722256.5T patent/DK3773715T3/da active
- 2019-03-28 MX MX2020010269A patent/MX2020010269A/es unknown
- 2019-03-28 EA EA202091989A patent/EA202091989A1/ru unknown
- 2019-03-28 AU AU2019243283A patent/AU2019243283C1/en active Active
- 2019-03-28 WO PCT/US2019/024633 patent/WO2019191464A1/fr active Application Filing
-
2020
- 2020-09-22 IL IL277514A patent/IL277514A/en unknown
-
2022
- 2022-08-03 JP JP2022123689A patent/JP7331219B2/ja active Active
-
2023
- 2023-08-09 JP JP2023130117A patent/JP2023166388A/ja active Pending
- 2023-10-11 AU AU2023248103A patent/AU2023248103A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020018099A2 (pt) | 2020-12-22 |
| DK3773715T3 (da) | 2024-05-27 |
| JP7331219B2 (ja) | 2023-08-22 |
| EP4327866A3 (fr) | 2024-03-20 |
| JP7119114B2 (ja) | 2022-08-16 |
| AU2019243283B2 (en) | 2023-07-27 |
| EA202091989A1 (ru) | 2021-01-13 |
| EP3773715B1 (fr) | 2024-05-08 |
| FI3773715T3 (fi) | 2024-05-30 |
| MX2020010269A (es) | 2020-11-06 |
| AU2019243283A1 (en) | 2020-09-24 |
| SG11202009526RA (en) | 2020-10-29 |
| US20210032325A1 (en) | 2021-02-04 |
| KR102552693B1 (ko) | 2023-07-07 |
| CN111936165A (zh) | 2020-11-13 |
| EP3773715A1 (fr) | 2021-02-17 |
| TW201946657A (zh) | 2019-12-16 |
| AU2023248103A1 (en) | 2023-11-09 |
| WO2019191464A1 (fr) | 2019-10-03 |
| AU2019243283C1 (en) | 2024-05-02 |
| EP4327866A2 (fr) | 2024-02-28 |
| IL277514A (en) | 2020-11-30 |
| TW202206104A (zh) | 2022-02-16 |
| TWI744617B (zh) | 2021-11-01 |
| JP2021517156A (ja) | 2021-07-15 |
| KR20200128101A (ko) | 2020-11-11 |
| JP2023166388A (ja) | 2023-11-21 |
| JP2022169562A (ja) | 2022-11-09 |
| CA3095297A1 (fr) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| MA52371A (fr) | Méthodes de traitement d'infections dues aux coronaviridae | |
| MA50056A (fr) | Procédés de traitement de tumeur | |
| MA52216A (fr) | Méthodes de traitement de la colite ulcéreuse | |
| MA45563A (fr) | Méthodes de traitement du cancer de l'ovaire | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| MA46102A (fr) | Composés de tétracycline et méthodes de traitement | |
| MA43374A (fr) | Méthodes de traitement de tumeurs malignes | |
| MA50514A (fr) | Méthodes de traitement du myélome multiple à haut risque | |
| MA50264A (fr) | Méthodes de traitement des infections de type hépatite b | |
| BR112018000933A2 (pt) | métodos de tratamento de um distúrbio de desenvolvimento | |
| MA42450A (fr) | Méthodes de traitement de la stéatose hépatique non alcoolique et/ou de la lipodystrophie | |
| MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
| MA53882A (fr) | Méthodes de traitement de la sclérose en plaques | |
| DK3393579T3 (da) | Øjenbehandlingssystem | |
| DK3318115T3 (da) | Maskine til behandling af svinegylle | |
| MA47820A (fr) | Traitement de la glycogénose de type iii | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
| MA47408A (fr) | Traitement du cancer | |
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| ES2893126T8 (es) | Métodos de tratamiento de afecciones oculares | |
| BR112018000204A2 (pt) | métodos de tratamento de colite | |
| MA54860A (fr) | Méthodes de traitement du myélome multiple | |
| FR3039368B1 (fr) | Procede de traitement cosmetique |